tiprankstipranks
VYNE Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-EarningsVYNE Earnings Report this Week: Is It a Buy, Ahead of Earnings?
2M ago
VYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
PremiumPress Releases
VYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
2M ago
VYNE Therapeutics Announces Positive Biomarker Data from Successful Phase 1b Trial of VYN201 for the Treatment of Vitiligo
PremiumPress Releases
VYNE Therapeutics Announces Positive Biomarker Data from Successful Phase 1b Trial of VYN201 for the Treatment of Vitiligo
4M ago
VYNE Therapeutics expects cash to fund operations through 2025
PremiumThe FlyVYNE Therapeutics expects cash to fund operations through 2025
5M ago
VYNE Therapeutics reports Q3 EPS ($201) vs. ($2.94) last year
PremiumThe Fly
VYNE Therapeutics reports Q3 EPS ($201) vs. ($2.94) last year
5M ago
VYNE Therapeutics to host virtual research and development day
PremiumThe Fly
VYNE Therapeutics to host virtual research and development day
6M ago
VYNE Therapeutics reports results from preclinical models for VYN202
PremiumThe FlyVYNE Therapeutics reports results from preclinical models for VYN202
6M ago
VYNE Therapeutics sells 10.65M shares at $2.245 in private placement
PremiumThe Fly
VYNE Therapeutics sells 10.65M shares at $2.245 in private placement
6M ago
VYNE Therapeutics Announces Private Placement of $88 Million
PremiumPress Releases
VYNE Therapeutics Announces Private Placement of $88 Million
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100